Literature DB >> 27060082

Identification of citrullinated peptides in the synovial fluid of patients with rheumatoid arthritis using LC-MALDI-TOF/TOF.

Fei Wang1, Fang-Fang Chen1, Wen-Bo Gao1, Hai-Yong Wang1, Ning-Wei Zhao2, Min Xu1, De-Yu Gao1, Wei Yu1, Xiao-Ling Yan1, Jian-Ning Zhao3, Xiao-Jun Li4,5.   

Abstract

The objective of the study is to investigate potential citrullinated autoantigens as targets of anti-citrullinated protein antibodies (ACPAs) response in synovial fluids (SFs) of patients with rheumatoid arthritis (RA). SFs from six RA patients and six osteoarthritis (OA) patients as controls were collected. The citrullinated proteins in SFs were extracted by immunoprecipitation with rabbit anti-citrulline antibodies. Matrix-assisted laser desorption/ionization time of flight mass spectrometry/time of flight mass spectrometry (MALDI-TOF/TOF) mass spectrometry was subsequently performed to discover a characteristic neutral loss to finally determine citrullinated autoantigens. A total of 182 citrullinated peptides and 200 citrullinated sites were identified in RA SFs, while 3 citrullinated peptides and 4 citrullinated sites were identified in OA SFs. The 182 citrullinated peptides from RA SFs and the 3 citrullinated peptides from OA SFs were derived from 83 and 3 autoantigens, respectively. Eighty-three autoantigens except protein-arginine deiminase type-2 (PADI2) and protein-arginine deiminase type-2 (PADI4) were over-citrullinated compared with controls, and the citrullinated sites of PADI2 and PADI4 were different in two groups. Interestingly, citrullinated histone H3.3 (H3F3A) was found in OA controls, but not in RA groups. The differential citrullinated proteins identified in RA SFs suggested potential autoantigens were targeted for ACPAs response and might contribute to the induction and perpetuation of complement activation and joint inflammation in RA.

Entities:  

Keywords:  Citrullinated protein; LC-MALDI-TOF/TOF; Rheumatoid arthritis; Synovial fluid

Mesh:

Substances:

Year:  2016        PMID: 27060082      PMCID: PMC4989008          DOI: 10.1007/s10067-016-3247-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the formation of inflammatory, invasive tissue, and rheumatoid pannus in synovial membranes, subsequently resulting in joint destruction and systemic complications. The related autoimmunity is often associated with certain major histocompatibility complex (MHC) types and the presence of anti-citrullinated protein antibodies (ACPAs) [1]. ACPAs are important biomarkers of RA and can be detected even before the clinical onset of the disease; consequently, they are recognized as a predictive and diagnostic marker. Furthermore, ACPAs in the inflammatory synovium bind to citrullinated autoantigens to form immune complexes (ICs), which lead to the development of inflammation [2-7]. Thus, a simple and effective method is needed to detect citrullinated proteins in the joint fluid from RA patients. Citrullination is a post-translational modification (PTM) involving the conversion of an arginine residue to a non-coded citrulline residue, catalyzed by peptidylarginine deiminases (PADIs). This PTM leads to the loss of a positive charge and a reduction in hydrogen-bonding ability [8]. The traditional method to detect citrullinated proteins in biological fluids is two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) followed by immunoblotting and Fourier transform ion cyclotron resonance (ICR) mass spectrometry (MS) analysis, which is labor-intensive and time-consuming [9-12]. Moreover, the mass shift of citrullination is very small (+1 Da), which can result in false positives [4,13]. Hao et al. [14] found that one specific signature of citrullination is that the neutral loss of 43 Da from the peptidyl-citrulline can be observed after collision-induced dissociation (CID) during triple quadruple/linear ion trap (Q-Trap) mass spectrometry, which indicates the elimination of isocyanic acid from the citrulline ureido group as shown in (Fig. 1). However, this technology has not been applied to human fluid because the complexity of the protein mixture made detection of low-abundance proteins very difficult. In addition, the low mass resolution of Q-trap MS prevented the reliable peptide and PTM characterization as in the high mass resolution of time-of-flight (TOF) MS. Thus, we first applied liquid chromatography-matrix-assisted laser desorption/ionization (LC-MALDI)-TOF/TOF to detect citrullinated proteins in human RA synovial fluid (SF).
Fig. 1

Schematic of the citrullinated peptide detection method. Step 1: citrullination of the protein. Step 2: the hydrogen bond is cleaved during CID of the citrullinated peptides, resulting in a signature 43-Da neutral loss from peptidyl-citrulline

Schematic of the citrullinated peptide detection method. Step 1: citrullination of the protein. Step 2: the hydrogen bond is cleaved during CID of the citrullinated peptides, resulting in a signature 43-Da neutral loss from peptidyl-citrulline In this study, citrullinated proteins were extracted by immunoprecipitation using agarose-conjugated rabbit anti-citrulline antibodies, followed by LC-MALDI-TOF/TOF MS analysis. The peptide sequences and citrullinated sites in RA SFs or osteoarthritis (OA) SFs were identified. The high-energy CID mode of MALDI-TOF/TOF (20 keV collision energy) was adopted to improve fragmentation efficiency for reliable peptide and PTM characterization, thereby enabling the identification of potential autoantigens for ACPAs.

Methods

Human sample collection

Samples of SFs were consecutively obtained from knee joints of patients with RA or patients with OA, as a control, during knee therapeutic arthrocentesis at the Department Osteology, Jinling Hospital, School of Medicine, Nanjing University from January 2011 to January 2012. In order to improve the possibility of the existence of citrullinated antigens, patients of RA fulfilling the criteria (serum ACPA >200 U/ml and synovial fluids ACPA >200 U/ml) were selected and SFs of patients who were diagnosed as OA were collected. Patients who had incomplete data were excluded. The diagnosis of RA was made according to the American College of Rheumatology/European League Against Rheumatism Collaborative Initiative 2010 criteria [15] and the diagnosis of OA was based on the 1986 clinical and radiological criteria for the diagnosis of knee OA developed by the American College of Rheumatology [16]. Finally, six patients with RA were obtained and six patients with OA were selected by random. The patients’ basic information and serologic profile are shown in (Table 1). Informed consent was obtained from all subjects and the study was approved by the local ethics committee (Nanjing, China).
Table 1

Clinical and laboratory characteristics of the RA and OA patients

DiagnosisSexAge (years)ACPA, (U/ml)RF (IU/ml)ESR (mm/h)CRP (mg/dl)Disease duration (years)DAS28
RAFemale61>20086.36425.134.28
RAFemale79>20039710942.744.93
RAFemale73>20040.64437.523.84
RAMale69>20024.52927.333.43
RAMale63>2001424477.853.72
RAMale70>2001028231.424.16
OAFemale68<0.5<2088.92_
OAFemale53<0.5<2077.83_
OAFemale63<0.5<2052.52_
OAMale69<0.5<2030.65_
OAMale54<0.5<2074.34_
OAMale58<0.5<20149.93_

ACPA anticitrullinated protein antibody, RF rheumatoid factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 disease activity score at 28 joints

Clinical and laboratory characteristics of the RA and OA patients ACPA anticitrullinated protein antibody, RF rheumatoid factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 disease activity score at 28 joints

Immunoprecipitation

All SF samples were centrifuged at 25,000×g for 10 min at 4 °C and the supernatants were stored separately in sterile conditions at −80 °C. EDTA was added at a final concentration of 50 mM, followed by centrifugation at 14,000×g for 10 min at 4 °C, and the supernatant or sample was transferred to a new vial. Protein concentrations were determined by BioSpec-nano (Shimadzu Biotech, Kyoto, Japan), and 1 mg was then subjected to immunoprecipitation [17,18]. Anti-citrulline polyclonal antibody (pAb; Abcam, Cambridge, USA) was cross-linked to protein G-Agarose (Sigma Aldrich, St Louis, MO, USA) with stable amide linkages according to the manufacturer’s instructions. Citrullinated proteins were immunoprecipitated by incubating the supernatant/sample with agarose-conjugated rabbit anti-citrulline antibodies overnight. The samples were washed three times with 50 mM ammonium acetate pH 7.4 and once with H2O, and the bound peptides were then eluted with acetonitrile/H2O (7:3 v/v) containing 5 mM HCl. The eluted peptides were subjected to desalting by C18 tip (SciLifeLab, Shanghai, China). The efficiency of immunoprecipitation was determined on equal amounts of protein/sample (OA, RA, washes of RA, and eluents of RA) by immunoblotting using anti-citrulline pAb.

Protein reduction, alkylation, and enzyme digestion

An additional 937 μL of 50 mM NH4HCO3 was added to the eluted proteins. The proteins were reduced by adding 10 μL of 0.5 M dithiothreitol (DTT) in 50 mM NH4HCO3 to a final concentration of 4 mM and incubated for 20 min at 56 °C. For alkylation, 27 μL of 0.55 M iodoacetamide was added, and the samples were incubated for 15 min at room temperature in the dark. The final concentration of the extracted proteins was approximately 2.4 mg/mL (total volume approximately 1250 μL) according to the optical density at 280 nm. ProteaseMax solution (10 μL of 1 %) was added together with 50 μL of 1 μg/μL LysC before incubation in a hydrated chamber at 37 °C overnight. The reaction was quenched by adding formic acid (FA; Fluka, Sigma) to a final concentration of 0.5 %. The digested peptides were then subjected to desalting by C18 tip (Shimadzu Biotech, Kyoto, Japan). Finally, the desalted peptides were immediately applied to a prominence nano2D-HPLC and Accuspot™ system (Shimadzu Biotech, Kyoto, Japan).

2D-NanoLC fractionation

A 5-μL aliquot of the desalted peptide/sample was loaded directly onto a PolySulfoethyl A Column (1.0 mm × 50 mm, 5 μm) for the first dimensional strong cation exchange separation (A = 10 mM FA, B = 600 mM FA). The samples were then subjected to a second dimensional RP separation using a Capillary EX-Nano MonoCap C-18 column (0.16 mm × 150 mm, 5 μm): A = 5 % acetonitrile + 0.1 % FA, B = 95 % acetonitrile + 0.1 % FA. The flow rate of the system was set at 4 μL/min post-split. The eluent passed through a UV/Vis detector (220 nm) and was mixed with α-cyano 4-hydroxycinnamic acid matrix (CHCA; 5 mg/ml in 50/50 acetonitrile/0.1 % trifluoroacetic acid) and deposited onto a stainless steel MALDI target using the Accuspot™ LC-MALDI deposition robot [19].

LC-MALDI-TOF/TOF MS analysis

Samples were deposited at a volume of ∼1 μL/spot. The signal-to-noise ratio (S/N) was determined using Launchpad version 2.9.1 software (Shimadzu Biotech, Kyoto, Japan). The limit of detection (LOD) was established with a S/N of 3:1. The m/z value was calibrated with 50 fmol each of human angiotensin II and human adrenocorticotropin fragment 18–39 and 250 fmol each of bovine insulin oxidized beta chain and bovine insulin as external standards. The m/z reported in MALDI-TOF/TOF (MALDI-7090, Shimadzu Kratos, Manchester, UK) was set in positive ion mode and a mass range of 1000–4000 Da. The peptide ions with high S/N (S/N > 10:1) were subjected to CID for subsequent MS/MS analysis.

Bioinformatics analysis

The raw MS/MS data were searched using the Mascot engine and then processed with PTM Finder™ Software (Shimadzu Kratos) using the following criteria: database, Swiss-Prot, human; enzyme, LysC; miscleavages, 2; static modifications, carbamidomethylation of cysteine (+57.02 Da); variable modifications, oxidation of methionine (+16.00 Da); neutral loss of isocyanic acid from peptidyl-citrulline (−43.02 Da); precursor ion tolerance, 0.3 Da; fragment ion tolerance, 0.8 Da. At this point, the citrullinated sites were identified by MS/MS analysis of the AA(8)AA ion because an ornithine residue (Orn) was expected to be the product after loss of a carbamyl group. Thus, the neutral loss of isocyanic acid from peptidyl-citrulline could be differentiated from the deamidation of peptidyl-asparagine or peptidyl-glutamine. All entries were filtered using a false positive rate of 1 % at the peptide levels, and false positives were removed. The citrullinated proteins from the RA SFs were further analyzed with DAVID Bioinformatics Resources (David 6.7 software, Bethesda, Maryland, USA) to understand their biological functions.

Results

A total of 182 citrullinated peptides and 200 citrullinated sites were identified in the RA SFs, while only three citrullinated peptides and four citrullinated sites were identified in the OA SFs (Tables 2 and 3). The 182 citrullinated peptides from the RA SFs were derived from 83 autoantigens, and the three citrullinated peptides from the OA SFs were derived from three autoantigens. The autoantigens in the RA SFs were over-citrullinated compared with the controls. Among these, 26 citrullinated proteins identified here have also been validated in previous studies (Table 4), which suggests that this strategy for identifying citrullinated peptides is highly effective.
Table 2

Citrullinated peptides and their deaminized sites identified by MALDI-TOF-MS in the RA SFs

Gene nameProtein IDPeptide sequenceCitrullinated sites
A2MA2MG_HUMANDNGCFRSSGSLLNNAIKR1081
GNRIAQWQSFQLEGGLKR174
EQAPHCICANGRQTVSWAVTPKR853
FQVDNNNRLLLQQVSLPELPGEYSMKR1297
ACTG1ACTG_HUMANDLYANTVLSGGTTMYPGIADRMQKR312
AGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKR28
ALBALBU_HUMANAWAVARLSQRFPKR246
LCTVATLRETYGEMADCCAKR105
VHTECCHGDLLECADDRADLAKR281
RMPCAEDYLSVVLNQLCVLHEKR469
YLYEIARRHPYFYAPELLFFAKR169
CCTESLVNRRPCFSALEVDETYVPKR509
ANXA1ANXA1_HUMANDITSDTSGDFRNALLSLAKR177
GTDVNVFNTILTTRSYPQLRRVFQKR228
APOA1APOA1_HUMANENGGARLAEYHAKR212
VEPLRAELQEGARQKR155
DSGRDYVSQFEGSALGKR51
PALEDLRQGLLPVLESFKR239
APOBAPOB_HUMANLEGTTRLTRKR3386
LTTNGRFREHNAKR1689
AEFTGRHDAHLNGKR3020
GNVATEISTERDLGQCDRFKR207
IREVTQRLNGEIQALELPQKR2449
RLIDLSIQNYHTFLIYITELLKR4519
YTYNYEAESSSGVPGTADSRSATRINCKR75
ARHGAP4F5GZW3_HUMANEEQEVSWTQYTQRKR486
AERFSSRGGRLGSSREHQSFRKR73, R77
ELLGKTSVRQGLGPASTTSPSPGPRSPKR889
LREAERQEEKRAGRSVPTTTAGATEAGPLRKR198
ARPC1BARC1B_HUMANQSSQRGLTARERFQNLDKR294, R299
PTLVILRINRAARCVRWAPNENKR100
C1RC1R_HUMANGFLAYYQAVDLDECASRSKR149
MQTRAGSRESEQGVYTCTAQGIWKR420
DCGQPRNLPNGDFRYTTTMGVNTYKR388
C1SC1S_HUMANAARLPVAPLRKR586
C2CO2_HUMANSSGQWQTPGATRSLSKR77
C3CO3_HUMAN RRHQQTVTIPPKR880
VLLDGVQNPRAEDLVGKR315
TVAVRTLDPERLGREGVQKR945
GYTQQLAFRQPSSAFAAFVKR1060
ITHRIHWESASLLRSEETKR1310
PDGVFQEDAPVIHQEMIGGLRNNNEKR1134
C4BCO4B_HUMANISARFSDGLESNSSTQFEVKR218
VDFTLSSERDFALLSLQVPLKR80
AAANQMRNFLVRASCRLRLEPGKR1675
SHALQLNNRQIRGLEEELQFSLGSKR1349
C4BPAC4BPA_HUMANPELVNGRLSVDKR493
NLRWTPYQGCEALCCPEPKR353
C6CO6_HUMANFRCDSGRCIARKR150
RSENINHNSAFKR289
SSRTSNPYRVPANLENVGFEVQTAEDDLKR225
C9CO9_HUMANNFRTEHYEEQIEAFKR213
CATCATA_HUMANNAIHTFVQSGSHLAAREKR522
CD44CD44_HUMANNGRYSISRTEAADLCKR41
EQWFGNRWHEGYRQTPKR407, R413
CFHCFAH_HUMAN RITCRNGQWSEPPKR1149, R1153
HGGLYHENMRRPYFPVAVGKR340
RGYRLSSRSHTLRTTCWDGKR1210, R1215
AQTTVTCMENGWSPTPRCIRVKR441
IPCSQPPQIEHGTINSSRSSQESYAHGTKR885
CNMGYEYSERGDAVCTESGWRPLPSCEEKR246
CFHR2FHR2_HUMANSHSFRAMCQNGKR254
CFICFAI_HUMANDNERVFSLQWGEVKR480
THRYQIWTTVVDWIHPDLKR389
CHMP2ACHM2A_HUMANMDLLFGRRKR8
DLVRTRRYVRKR71
CLCLEG10_HUMANYQVMVNGQSSYTFDHRIKR115
CPCERU_HUMANALYLQYTDETFRTTIEKR81
NLASRPYTFHSHGITYYKR115
ENLTAPGSDSAVFFEQGTTRIGGSYKR415
DNEDFQESNRMYSVNGYTFGSLPGLSMCAEDRVKR258
NMATRPYSIHAHGVQTESSTVTPTLPGETLTYVWKR830
CPB2CBPB2_HUMANDHEELSLVASEAVRAIEKR342
CTLA4CTLA4_HUMANAMHVAQPAVVLASSRGIASFVCEYASPGKR51
AQLNLATRTWPCTLLFFLLFIPVFCKR18
ENO1ENOA_HUMANTGAPCRSERLAKR403
LAQANGWGVMVSHRSGETEDTFIADLVVGLCTGQIKR372
F2THRB_HUMANYTACETARTPRDKR94, R97
DSTRIRITDNMFCAGYKR541
FF3AFF3_HUMANDFLTDRSNQSHLVGVPKR111
EAAANGGSGPRAPVGSINARTTSDIAKR745
YTSEDLTSSSRPNGNSLFTSASSSKR926
SPPAAVAVAVSAAAPPPAVPCAPAENAPAPARRSAGKR606
FGAFIBA_HUMANNVRAQLVDMKR160
GLIDEVNQDFTNRINKR84
FGBFIBB_HUMANREEAPSLRPAPPPISGGGYRARPAKR60, R72
EDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKR445
FGGFIBG_HUMANYEASILTHDSSIRYLQEIYNSNNQKR134
YTGNTYRVGDTYERPKR106
WLPSSSPVTGYRVTTTPKR1573
DNRGNLLQCICTGNGRGEWKR265
GCVTDB_HUMANHLSLLTTLSNRVCSQYAAYGEKR218
HQPQEFPTYVEPTNDEICEAFRKR149
RSDFASNCCSINSPPLYCDSEIDAELKR445
H1FXH1X_HUMANVPWFDQQNGRTYLKR86
YSQLVVETIRRLGERNGSSLAKR57, R62
H2AFYH2AY_HUMANSIAFPSIGSGRNGFPKR318
HABP2HABP2_HUMANEEFHEQSFRVEKR391
FCEIGSDDCYVGDGYSYRGKR203
LIANTLCNSRQLYDHMIDDSMICAGNLQKR480
HIST2H2ACH2A2C_HUMANTRIIPRHLQLAIRNDEELNKR89
GNYAERVGAGAPVYMAAVLEYLTAEILELAGNAARDNKR43, R72
HMGB2HMGB2_HUMANMSSYAFFVQTCREEHKR24
HNRNPA1L2RA1L2_HUMANGGNFGGRSSGPYGGGGQYFAKR284
HPHPT_HUMANVSVNERVMPICLPSKR261
YVMLPVADQDQCIRHYEGSTVPEKR311
HPRHPTR_HUMANVLVNERVMPICLPSKR203
HPXHEMO_HUMANNFPSPVDAAFRQGHNSVFLIKR102
HSP90AA1Q8TBA7_HUMANAQALRDNSTMGYMAAKR620
HNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKR173
HSPA1AHSP71_HUMANLLQDFFNGRDLNKR357
EIAEAYLGYPVTNAVITVPAYFNDSQRQATKR155
HSPA5GRP78_HUMANSDIDEIVLVGGSTRIPKR368
RLIGRTWNDPSVQQDIKR98
Ig kappa chain V-II region RPMI 6410KV206_HUMANVSNRDSGVPDRFSGSGSGTDFTLKR79
Ig lambda chain V-II region NEILV202_HUMAN RPSGVSNRFSGSKR56, R63
Ig lambda chain V-II region NIG-84LV211_HUMANLLIYDVNSRPSGISNRFSGSKR56, R63
IGHA1IGHA1_HUMANYLTWASRQEPSQGTTTFAVTSILRVAAEDWKR282
IGHG3IGHG3_HUMANSCDTPPPCPRCPEPKR128
TPLGDTTHTCPRCPEPKR113
ING4ING4_HUMANWFCPRCSQERKR241
ITIH2ITIH2_HUMANRLSNENHGIAQRIYGNQDTSSQLKR475
TILDDLRAEDHFSVIDFNQNIRTWRNDLISATKR356, R359
KNG1KNG1_HUMANICVGCPRDIPTNSPELEETLTHTITKR268
KRT33BKT33B_HUMANETMQFLNDRLASYLEKR66
LBRLBR_HUMANEARREVEVKR111
PLTSFRQRKR61
SARRSASASHQADIKR96
ELAVRTFEVTPIRAKR195
APRNDLSPASSGNAVYDFFIGRELNPRIGTFDLKR353
LCP1PLSL_HUMANGDEEGVPAVVIDMSGLREKR316
ALENDPDCRHVIPMNPNTNDLFNAVGDGIVLCKR141
LGALS3BPLG3BP_HUMANSGGSDRTIAYENKR514
SQLVYQSRRGPLVKR436
LRG1A2GL_HUMANALGHLDLSGNRLRKR175
LQVLGKDLLLPQPDLRYLFLNGNKR239
MAPRE1MARE1_HUMANPLTSSSAAPQRPISTQRTAAAPKR168
MMP8MMP8_HUMANFYQLPSNQYQSTRKR52
MNDAMNDA_HUMANINQEEVGLAAPAPTARNKR119
NCF1NCF1_HUMANSGQDVSQAQRQIKR292
STATDITGPIILQTYRAIANYEKR162
ORM1A1AG1_HUMANEQLGEFYEALDCLRIPKR167
PABPC1PABP1_HUMANAVTEMNGRIVATKR356
PVRIMWSQRDPSLRKR89, R94
ITGMLLEIDNSELLHMLESPESLRSKR604
PADI2PADI2_HUMANVGVFYVENPFFGQRYIHILGRRKR225, R233
PADI4PADI4_HUMANGFRLLLASPRSCYKR495
TLREHNSFVERCIDWNRELLKR536
PFGPVINGRCCLEEKR609
POFUT2OFUT2_HUMANVFVATDAVRKR337
DFIWGHRQDVPSLEGAVRKR315
PPIAPPIA_HUMANEGMNIVEAMERFGSRNGKR148
PRG4PRG4_HUMANDQYYNIDVPSRTARAITTRSGQTLSKR1386, R1391
PRKCDKPCD_HUMANQSMRSEDEAKR132
SPRDYSNFDQEFLNEKR628
IIGRCTGTAANSRDTIFQKR216
PTPN22PTN22_HUMANGPRNPPPTWNIR499
PAESVQSNNSSSFLNFGFANRFSKR491
SAA2SAA2_HUMANRGPGGAWAAEVISNARENIQRLTGRGAEDSLADQAANKR80, R89
SERPINA3AACT_HUMANADLSGITGARNLAVSQVVHKR350
SERPINC1ANT3_HUMANLVSANRLFGDKR177
IPEATNRRVWELSKR78
ANSRFATTFYQHLADSKR89
SLC22A4S22A4_HUMANVPLTTSLFFVGVLLGSFVSGQLSDRFGRKR166
STAT4STAT4_HUMANNVSTLSNRRFVLCGTNVKR173
SLQSSSVSERQRNVEHKVAAIKR139
FHGNPMHVAVVISNCLREERRILAAANMPVQGPLEKR110
TAGLN2TAGL2_HUMANMANRGPAYGLSREVQQKR4
TFTRFE_HUMANCSTSSLLEACTFRRPR696
EGYYGYTGAFRCLVEKR541
ADRDQYELLCLDNTRKR239, R251
TNCTENA_HUMANNGRENFYQNWKR2033
RVTTTRLDAPSQIEVKR802
VEAARNLTVPGSLRAVDIPGLKR1127
PDTEYEVSLISRRGDMSSNPAKR878
ETFTTGLDAPRNLRRVSQTDNSITLEWRNGKR897
TNCTENA_HUMANVPEITRTVSGNTVEYALTDLEPATEYTLRIFAEKR1866
TNFAIP6TSG6_HUMANNFLAGRFSHLR273
VIMVIME_HUMANMALDIEIATYRKR401
PDLTAALRDVRQQYESVAAKR270, R273
VPRPBVPRBP_HUMANFISGTPRRKR707
SPFGSSFRTFNATDYKR1334

Citrullinated residues are indicated with a bold R

Table 3

Citrullinated peptides and their deaminized sites identified by MALDI-TOF-MS in the OA SFs

Gene nameProtein IDPeptide sequenceCitrullinated sites
H3F3AH33_HUMANDIQLARRIRGERAR130
PADI2PADI2_HUMANGFPVVLDSPRDGNLKR373
PADI4PADI4_HUMANTLPVVFDSPRNRGLKR372, R374

Citrullinated residues are indicated with a bold R

Table 4

26 citrullinated proteins in our study were validated in previous studies

Protein IDReferences
Arginine deiminase type-4[19]
Alpha-1-acid glycoprotein 1[12]
Alpha-2-macroglobulin[12]
Annexin A1[12]
Apolipoprotein A-I[12]
Apolipoprotein B-100[12]
Ceruloplasmin[12]
C4b-binding protein alpha chain[12]
Complement C2[12]
Complement C4-B[12]
Complement factor H[12]
Enolase[12,20]
Fibrinogen[20]
Fibronectin[12]
Hemopexin[12]
HSP90[12]
Histone[8,21]
Inter-alpha-trypsin inhibitor heavy chain H2[12]
Myeloid cell nuclear differentiation antigen[12]
Plastin-2[12,22]
Proteoglycan 4[12]
Serotransferrin[12]
Serum albumin[12]
Tenascin[12]
Vitamin D-binding protein[12]
Vimentin[11]
Citrullinated peptides and their deaminized sites identified by MALDI-TOF-MS in the RA SFs Citrullinated residues are indicated with a bold R Citrullinated peptides and their deaminized sites identified by MALDI-TOF-MS in the OA SFs Citrullinated residues are indicated with a bold R 26 citrullinated proteins in our study were validated in previous studies Functional analysis of the identified citrullinated proteins in the RA group was performed with David 6.7 software. The categories of “disease” and “gene ontology” reported a significant enrichment of RA and acute inflammatory response-associated genes, which corresponded to the physiological status of the patients in the present study (Supplement Fig. 1). Furthermore, genes involved in the enriched pathways in the list were associated with complement and coagulation cascades (Supplement Fig. 2). Additionally, proteins that were involved in cell differentiation, metabolism, redox state and apoptosis, regulation and transport, immune response and acute phase, structural and cell adhesion, and other groups based on the NCBI and UniProt database information are shown in (Fig. 2a). Moreover, the proteins were also classified by their subcellular location, as described in (Fig. 2b). The results of our analysis demonstrated that the citrullinated proteins obtained with our protocol provide reliable data on the state of citrullination in RA SF.
Fig. 2

Classification by a function and b subcellular location of the proteins identified in the RA SFs

Classification by a function and b subcellular location of the proteins identified in the RA SFs

Discussion

The major methods used currently to identify citrullinated proteins employ 2D-PAGE followed by immunoblotting and Fourier transform ion cyclotron resonance mass spectrometry analysis. For example, J.B.C. van Beers et al. found 192 proteins including 53 citrullinated proteins with their citrullinated residues in RA SFs [12]. One problem with this method is the small mass shift (+1 Da) from the conversion of peptidyl arginine to Cit, which is challenging for mass detection to distinguish. In the present study, citrullinated proteins were effectively enriched following immunoprecipitation (Supplement Fig. 1). NanoLC was then used to fractionate the tryptic digests of citrullinated proteins to improve the sensitivity and dynamic range of protein identification. With this method, not only are peptides of the same nominal mass isolated by temporal separation, but signal suppression is also reduced because of the separation of low- and high-abundance peptides. Importantly, the unique LC-MALDI peak picking algorithm promotes the MS/MS of selected ions at the apex of the eluting chromatographic peak to allow the most efficient data acquisition. This is not often the case with ES LC-MS/MS, where MS/MS acquisition is often taken on the rising edge of the eluting chromatographic peak. In addition, the high-energy CID mode of MALDI-TOF/TOF (20 keV collision energy, MALDI-7090) allowed us to determine the citrullinated sites more easily, according to the characteristic neutral loss of an isocyanic acid group from peptidyl-citrulline. A number of chaperone molecules were identified within the SFs, particularly heat shock 70 kDa protein 1A/1B (HSPA1A), glucose-regulated protein 78 kDa (GRP78 or HSPA5), and HSP90AA1, members of the stress-inducible heat-shock protein 70 family. Also, we previously found GRP75 (HSP70) and binding immunoglobulin protein (BiP or GRP78) in RA synovial fibroblast-like synoviocytes (FLSs) [20]. Citrullinated BiP induces anti-CCP and anti-citrullinated fibrinogen antibodies and exacerbates collagen-induced arthritis in mice, and deaminated HSP90 was identified as a diagnostic autoantigen for a potentially serious manifestation of RA [10,21]. Recently, HSPs have been reported that not only act as chaperones during protein folding but also play a role between ubiquitin E3 ligase and the proteasome to inhibit proinflammatory NF-ΚB signaling [22]. In addition, both canonical and non-canonical NF-ΚBs are overexpressed in RA and are associated with the persistence of inflammation in RA [23]. Thus, citrullination of HSP may contribute to the chronic inflammation in the synovium or dysregulation of RA synovial fibroblasts, suggesting that citrullination may correlate with complement activation and the perpetuation of RA. In a previous study from our group, we also reported that the elevated Annexin A11 in FLSs may be associated with the extensive synovial fibroblast-like synoviocytes hyperplasia. Additionally, in the extracellular environment defined as synovial fluid, we found citrullinated AnnexinA1, another member of the annexin superfamily of structurally related Ca2+-dependent phospholipid-binding proteins. Several other studies have demonstrated that AnnexinA1 is a glucocorticoid-induced molecule that can be transferred into cartilage and can modulate T cell function and the adaptive immune responses relevant to RA [24,25]. Consistent with this, treatment of mice with dexamethasone promotes potent antiarthritic effects that are dynamically attenuated in AnxA1−/− mice [26]. Our observations on citrullinated Annexin A1 reflect the possibility that citrullinated or non-citrullinated Annexin may be a target to minimize glucocorticoid use in RA. The different citrullinated sites of PADI2 and PADI4 in the two groups suggest new potential biomarkers for RA. PADI2 and PADI4 are the only PAD isotypes expressed in the synovial tissue of patients with RA, and they were reported to induce differentiation and apoptosis [27]. PADI4, found in the cell nucleus, mediated gene transcription by regulating arginine citrullination and methylation in histones H1, H3, and H4 and was autocitrullinated during cell activation [8,28,29]. Interestingly, citrullinated H3F3A was found in the OA controls, but not in the RA group. In addition, histones H1x and H2A were only citrullinated in the RA group. These results suggest that PADI2 and PADI4 represent a heterogeneous subtype with different citrullinated sites targeting multiple structural domains, where the specific citrullinated site may predict a specific disease. The exact mechanism underlying this phenomenon remains to be elucidated. Although we identified the potential antigens for ACPA, some limitations remain, including the amount of patients was small, thus we pooled all samples per group to gain more sensitivity and to find more citrullinated antigens; results merely compared with previous studies; the validated process used only one method of mass spectrometry and was only on the basis of mass-spectrometry-based proteomics, so we performed DAVID Bioinformatics Resources to classify these genes corresponding to citrullinated proteins, at the same time, estimate and verify the reliability. Further studies will employ western blot to identify some selected potential autoantigens. At the same time, we will collect samples of synovial fluid or serum of RA patients as more as possible and then test antibodies corresponding to autoantigens in synovial fluid or serum of RA patients in order to obtain reliable results from clinical data. These limitations indicate the need for larger validation studies and prospective SFs studies in groups where larger samples are available. Overall, we demonstrated a simple and efficient strategy for detecting citrullinated proteins and citrullinated sites in human RA SFs. In addition to the previously detected citrullinated proteins in RA SF, the novel citrullinated proteins identified by the data here may represent new antigens for ACPAs, as well as new markers for diagnosis. More importantly, this data will contribute to the search for the etiopathogenesis of, and new therapeutic targets for RA. Below is the link to the electronic supplementary material. (DOCX 1136 kb)
  28 in total

Review 1.  Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms.

Authors:  Sylviane Muller; Marko Radic
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

2.  Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation.

Authors:  Felipe Andrade; Erika Darrah; Marjan Gucek; Robert N Cole; Antony Rosen; Xiaoming Zhu
Journal:  Arthritis Rheum       Date:  2010-06

3.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.

Authors:  Toshiya Matsubara; Ayako Mita; Kohtaro Minami; Tetsuya Hosooka; Sohei Kitazawa; Kenichi Takahashi; Yoshikazu Tamori; Norihide Yokoi; Makoto Watanabe; Ei-Ichi Matsuo; Osamu Nishimura; Susumu Seino
Journal:  Cell Metab       Date:  2012-01-04       Impact factor: 27.287

4.  The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and β-actin.

Authors:  Joyce J B C van Beers; Carla M Schwarte; Judith Stammen-Vogelzangs; Els Oosterink; Borut Božič; Ger J M Pruijn
Journal:  Arthritis Rheum       Date:  2013-01

5.  Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides.

Authors:  Mathias Scinocca; David A Bell; Maud Racapé; Radha Joseph; Gary Shaw; John K McCormick; Dafna D Gladman; Janet Pope; Lillian Barra; Ewa Cairns
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

6.  Neutral loss of isocyanic acid in peptide CID spectra: a novel diagnostic marker for mass spectrometric identification of protein citrullination.

Authors:  Gang Hao; Danchen Wang; Jane Gu; Qiuying Shen; Steven S Gross; Yanming Wang
Journal:  J Am Soc Mass Spectrom       Date:  2008-12-30       Impact factor: 3.109

7.  A novel role for protein arginine deiminase 4 in pluripotency: the emerging role of citrullinated histone H1 in cellular programming.

Authors:  Daniel J Slade; Sachi Horibata; Scott A Coonrod; Paul R Thompson
Journal:  Bioessays       Date:  2014-05-30       Impact factor: 4.345

8.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis.

Authors:  Soumya Raychaudhuri; Cynthia Sandor; Eli A Stahl; Jan Freudenberg; Hye-Soon Lee; Xiaoming Jia; Lars Alfredsson; Leonid Padyukov; Lars Klareskog; Jane Worthington; Katherine A Siminovitch; Sang-Cheol Bae; Robert M Plenge; Peter K Gregersen; Paul I W de Bakker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330

Review 9.  Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?

Authors:  Ae R Noort; Paul P Tak; Sander W Tas
Journal:  Arthritis Res Ther       Date:  2015-01-28       Impact factor: 5.156

10.  Citrullination regulates pluripotency and histone H1 binding to chromatin.

Authors:  Maria A Christophorou; Gonçalo Castelo-Branco; Richard P Halley-Stott; Clara Slade Oliveira; Remco Loos; Aliaksandra Radzisheuskaya; Kerri A Mowen; Paul Bertone; José C R Silva; Magdalena Zernicka-Goetz; Michael L Nielsen; John B Gurdon; Tony Kouzarides
Journal:  Nature       Date:  2014-01-26       Impact factor: 49.962

View more
  29 in total

1.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

Review 2.  Individuals at risk of seropositive rheumatoid arthritis: the evolving story.

Authors:  S Rantapää Dahlqvist; F Andrade
Journal:  J Intern Med       Date:  2019-10-21       Impact factor: 8.989

3.  Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q.

Authors:  Leonie M Vogt; Ewa Kwasniewicz; Simone Talens; Carsten Scavenius; Ewa Bielecka; Kristina N Ekdahl; Jan J Enghild; Matthias Mörgelin; Tore Saxne; Jan Potempa; Anna M Blom
Journal:  J Immunol       Date:  2020-04-06       Impact factor: 5.422

Review 4.  Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  Karen M Doody; Nunzio Bottini; Gary S Firestein
Journal:  Epigenomics       Date:  2017-03-21       Impact factor: 4.778

Review 5.  Rheumatoid arthritis and citrullination.

Authors:  Erika Darrah; Felipe Andrade
Journal:  Curr Opin Rheumatol       Date:  2018-01       Impact factor: 5.006

6.  Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.

Authors:  Bingtong Li; Ping Li; Liqi Bi
Journal:  Clin Rheumatol       Date:  2019-11-22       Impact factor: 2.980

Review 7.  Insights into the study and origin of the citrullinome in rheumatoid arthritis.

Authors:  Justyna Fert-Bober; Erika Darrah; Felipe Andrade
Journal:  Immunol Rev       Date:  2019-12-25       Impact factor: 12.988

Review 8.  Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis.

Authors:  Jie Huang; Xuekun Fu; Xinxin Chen; Zheng Li; Yuhong Huang; Chao Liang
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

9.  Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.

Authors:  Zihao Zheng; Aisha M Mergaert; Lauren M Fahmy; Mandar Bawadekar; Caitlyn L Holmes; Irene M Ong; Alan J Bridges; Michael A Newton; Miriam A Shelef
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 15.483

Review 10.  Citrullination and PAD Enzyme Biology in Type 1 Diabetes - Regulators of Inflammation, Autoimmunity, and Pathology.

Authors:  Mei-Ling Yang; Fernanda M C Sodré; Mark J Mamula; Lut Overbergh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.